Alunbrig (Brigatinib)
- Medicine name: Alunbrig
- Generic name: Brigatinib
- Dosage form & strength: tablets in 180 mg, 90 mg, or 30 mg.
- Manufactured by: Takeda Pharmaceutical Company Limited
Brigatinib is a tyrosine kinase inhibitor used in the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Recommended dosage:
The recommended dosage of Alunbrig (Brigatinib) is 90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily.
Healthcare professionals recommend administering Alunbrig tablets orally via the mouth. One may take the tablets of Alunbrig with or without food.
- Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with Alunbrig. One should monitor for new or worsening respiratory symptoms, particularly during the first week of initiating Alunbrig.
- Hypertension was seen in the patients who are receiving Alunbrig. One should control blood pressure before treatment with Alunbrig. And one should monitor blood pressure after 2 weeks and at least monthly after that during treatment with Alunbrig.
- Grade 3 bradycardia occurred in the patients who were receiving Alunbrig. One should monitor heart rate and blood pressure during treatment with Alunbrig. And one should monitor patients more frequently if concomitant use of drugs known to cause bradycardia cannot be avoided.
- Alunbrig can cause fetal harm when administered to pregnant women. There is no clinical data on the use of Alunbrig in pregnant women. Healthcare professionals advise females of reproductive potential to use effective non-hormonal contraception during treatment with Alunbrig and for at least 4 months following the final dose. One should advise males with female partners of reproductive potential to use effective contraception during treatment and at least 3 months after the last dose of Alunbrig.
What documents are required to import ALUNBRIG to India?
ALUNBRIG (Brigatinib) tablets can be imported only by patients or government hospitals in the patients’ names.
The following documentation is needed to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity proof (issued by Govt of India)
How does the order confirm?
The order will be confirmed only after the receipt of:
- A valid prescription by healthcare professionals.
- Import permit if applicable.
Is ALUNBRIG available in India?
ALUNBRIG (Brigatinib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Alunbrig in India.
- Medicine Price.
- Finding Genuine and reliable sources from Canada, Europe, the USA and Australia
- Ensuring 100% transparency.
ALUNBRIG can be made available to patients, doctors and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after receiving a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of ALUNBRIG (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Alunbrig price in India.
We guarantee quality and delivery anywhere in the world per the buyer’s requirements.
Indian Pharma Network can source the ALUNBRIG from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Brigatinib?
The generic trade name for the drug Bringatinib is Alunbrig.
What are the ingredients of the medicine Alunbrig?
The active ingredient in the medicine is Brigatinib, with inactive ingredients lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica.
Does the FDA approve Alunbrig?
Yes, Alunbrig is approved by the FDA. Date of approval: April 28, 2017.
What is Alunbrig?
Alunbrig contains Brigatinib, a tyrosine kinase inhibitor with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations.
What is the dosage and form of Alunbrig supplied?
Alunbrig is supplied as tablets: 180 mg, 90 mg, or 30 mg for oral administration.
What are the most common side effects due to Alunbrig?
The most common side effects of Alunbrig are diarrhoea, fatigue, nausea, rash, cough, muscle pain, headache, high blood pressure, vomiting and difficulty breathing.
How much does Alunbrig cost in India?
The Alunbrig cost in India is sensibly reasonable. To authenticate this drug, you can call or WhatsApp +91-9310090915 or email info@indianpharmanetwork.in.
How to store the medicine Alunbrig?
One should store Alunbrig at room temperature 20°C to 25°C (68°F to 77°F).
Is it safe to buy Alunbrig online?
To buy Alunbrig (Brigatinib) online, always look for an authentic, legitimate, WHO-GDP and ISO-certified Pharmaceutical Wholesaler/Distributor/Supplier.
What are the Highlights of prescribing information for Alunbrig?
Click Here for full Alunbrig prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.